Influenza A virus H1N1 vaccine - Seqirus

Drug Profile

Influenza A virus H1N1 vaccine - Seqirus

Alternative Names: A(H1N1) influenza vaccine - Seqirus; A/H1N1-SOIV (swine flu) vaccine - Seqirus; A/H1N1v vaccines - Seqirus; Adjuvanted cell culture-based influenza A H1N1 (2009) monovalent vaccine (Celtura®) - Seqirus; Celtura; Fluvirin A(H1N1) monovalent vaccine - Seqirus; Fluvirin A/H1N1; Focetria; H1N1 pandemic influenza virus vaccine - Seqirus; MF59-eH1N1 - Seqirus; Monovalent A/H1N1 influenza vaccine - Seqirus; Swine flu vaccine - Seqirus; Swine-origin influenza A/H1N1 virus monovalent subunit vaccine - Seqirus

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Seqirus
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 09 Nov 2015 CSL’s influenza vaccine business started operating under the brand name Seqirus
  • 18 Jul 2011 US FDA approves Fluvirin® for the 2011-2012 influenza season in USA
  • 13 Jun 2011 Novartis completes a Phase-III trial in Influenza-A virus H1N1 subtype in Belgium, Germany and Switzerland (NCT00970177)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top